Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty

NCT04319848

Status	RECRUITING
Phase	Phase 1
Sponsor	Singapore Eye Research Institute
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (3)

- Patients who have mild to moderate corneal endothelial decompensation or bullous keratopathy, but with minimal corneal stromal scarring resulting from a variety of conditions including:
- Fuchs' endothelial dystrophy
- Post-surgical corneal decompensation (irreversible) - all forms of pseudophakic or aphakic bullous keratopathy

Exclusion (10)

- Severe forms or late stage presentation of corneal decompensation with severe corneal stromal scarring, unsuitable for TE-EK surgery as opposed to penetrating keratoplasty
- Patients with complex anterior segment complications precluding a successful TE-EK procedure
- Patients who have other forms of endothelial dystrophy, traumatic corneal decompensation, or post-inflammatory corneal decompensation
- Post-laser iridotomy or glaucoma related corneal decompensation
- Patients not keen to participate in the clinical trial

... and 5 more (see full listing online)

Locations (1 total)

Singapore Eye Research Institute, Singapore, Singapore